… COV, a combination of the monoclonal antibodies … coronavirus disease 2019 (Covid-19).
REGEN-COV has activity in vitro against current severe acute respiratory syndrome coronavirus …

… from complications of Covid-19. When we initiated the REGEN-COV program, we hypothesized
that a combination of neutralizing, noncompeting monoclonal antibodies could have …

… already received two doses of COVID-19 vaccines, we aimed to … combination of vaccinations:
two doses of BNT162b2 followed by one dose of BNT162b2 booster (BBB); Combination of …

… and the potential benefit of combining antibodies to defend against emerging viral variants.
… from mild COVID-19 demonstrated neutralizing antibody and S-binding antibody titres that …

… -2 neutralizing antibodies (nAbs) in the clinical management of COVID-19 and provide an …
evaluating the combination of bamlanivimab with etesevimab in ambulatory COVID-19 patients…

… contact, treatment with subcutaneous casirivimab and imdevimab antibody combination
vs placebo significantly reduced the incidence of symptomatic COVID-19 over 28 days. …

… et al; COVID-19 Phase 3 Prevention Trial Team. Effect of subcutaneous casirivimab and
imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early …

… A combination (cocktail) of two antibodies that recognize different non-competing epitopes
of the RBD or the spike protein of SARS-CoV-2 has been developed for clinical trials to …

… in coronavirus disease 2019 (COVID-19) outpatients (NCT04425629) found that the
REGEN-COV ® antibody combination, … for antibodies against severe acute respiratory syndrome …

… The full analysis set included the first 275 patients with Covid-19 symptoms who underwent
randomization in the combined phase 1–2 portions of the trial. A sample of 275 patients (72 …